{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"groups":[{"description":"Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and azacitidine SC or IV over 10-40 minutes on days 1-7. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given SC or IV\n\nQuizartinib: Given PO","id":"OG000","title":"Phase 1 Arm I (Quizartinib, Azacitidine)"},{"description":"Patients receive quizartinib PO QD on days 5-28 of cycle 1 and on days 1-28 of subsequent cycles and cytarabine SC BID on days 1-10. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nCytarabine: Given SC\n\nQuizartinib: Given PO","id":"OG001","title":"Phase 1 Arm II (Quizartinib, Cytarabine)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"At 28 days","title":"Maximum Tolerated Dose of Quizartinib (Phase I)","type":"PRIMARY","unitOfMeasure":"Milligrams"}